Latest news

• Sandoz finally wins FDA approval for Neulasta biosimilar

  Follows a three year wait since initial rejection in 2016. Sandoz, Novartis’ generics and biosimilar division, has finally won approval for its Neulasta biosimilar Ziextenzo (pegfilgrastim) following a three year wait. ... The study compared Sandoz’

• Amgen buys Danish partner Nuevolution for $167m

  The company is starting to face biosimilar competition for white blood cell stimulator Neulasta (pegfilgrastim) as well as generic encroachment on Sensipar (cinacalcet) for secondary hyperparathyroidism, which together accounted for around

• Amgen CEO says Aimovig is “one of most successful launches”

  Overall, Amgen posted a 2% rise in revenues to $5.78bn in the quarter, despite pressure on older drugs like while blood cell booster Neulasta (pegfilgrastim) which showed the first signs

• Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

  The three biosimilars are: Mylan’s Hulio (adalimumab), a version of AbbVie’s big-selling Humira for the treatment of certain inflammatory and autoimmune disorders; and Accord Healthcare’s Pelgraz (pegfilgrastim) ... and ERA Consulting’s Udenyca

• Novartis doubles down on biosimilars with Biocon alliance

  drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.